Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 10mg;   - soft gelatin capsule - 10 mg - active: ciclosporin 10mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 25mg;   - soft gelatin capsule - 25 mg - active: ciclosporin 25mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol iron oxide black polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 50mg;   - soft gelatin capsule - 50 mg - active: ciclosporin 50mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 50 mg/ml - solution for infusion - 250 mg/5ml - active: ciclosporin 50 mg/ml excipient: ethanol polyoxyl 35 castor oil - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 150mg;  ;  ;   - film coated tablet - 150 mg - active: oxcarbazepine 150mg       excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide black iron oxide red iron oxide yellow macrogol 4000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 300mg;  ;   - film coated tablet - 300 mg - active: oxcarbazepine 300mg     excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide yellow macrogol 8000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 600mg;  ;  ;   - film coated tablet - 600 mg - active: oxcarbazepine 600mg       excipient: colloidal silicon dioxide crospovidone hypromellose   iron oxide black iron oxide red macrogol 4000 magnesium stearate powdered cellulose purified talc titanium dioxide - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 60 mg/ml;  ;   - oral suspension - 60 mg/ml - active: oxcarbazepine 60 mg/ml     excipient: ascorbic acid citrus limon dispersible cellulose macrogol stearate 400 methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified water saccharin sodium sorbic acid sorbitol - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 22.4mg equivalent to octreotide 20 mg;   - powder for injection - 20 mg - active: octreotide acetate 22.4mg equivalent to octreotide 20 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas